Эритропоэтин у больных сахарным диабетом I типа (обзор)

Эритропоэтин у больных сахарным диабетом I типа (обзор)

Автор: Хантакова Екатерина Александровна, Хамнуева Лариса Юрьевна

Журнал: Саратовский научно-медицинский журнал @ssmj

Рубрика: Эндокринология

Статья в выпуске: 1 т.8, 2012 года.

Бесплатный доступ

Анализируется литература, посвященная проблеме регуляции эритропоэтина у больных сахарным диабетом I типа. Обсуждается связь нарушения секреции эритропоэтина с развитием и прогрессированием осложнений сахарного диабета. Рассматриваются различные плейотропные эффекты эритропоэтина

Диабетическая нефропатия, диабетическая ретинопатия, сахарный диабет 1-го типа, эритропоэтин

Короткий адрес: https://sciup.org/14917493

IDR: 14917493

Список литературы Эритропоэтин у больных сахарным диабетом I типа (обзор)

  • Шестакова М.В., Дедов И. И. Сахарный диабет и хроническая болезнь почек. М.: ООО «Медицинское информационное агентство», 2009. 482 с.
  • Бондарь И. А., Климонтов В. В., Рогова И. П., Надеев А. П. Почки при сахарном диабете: патоморфология, патогенез, ранняя диагностика, лечение. Новосибирск: Изд-во НГТУ, 2008. 272 с.
  • Ильин А. П., Богоявленский В.Ф., Смурякова Е.Е. Особенности течения хронической почечной недостаточности у больных сахарным диабетом, находившихся на гемодиализе//Пробл. эндокр. 2004. Т. 50, № 1. С. 13-18.
  • Prevalence of chronic kidney disease in the United States/J. Coresh, E. Selvin, L.A. Stevens [et al.]//JAMA. 2007. Vol. 298. P. 2038-2047.
  • Erythropoietin response to hypoxia in patients with diabetic autonomic neuropathy and non-diabetic chronic renal failure/D.R. Bosman, C.A. Osborne, J.T. Marsden [et al.]//Diabet. Med. 2002. Vol. 19. P. 65-69.
  • Anemia With Impaired Erythropoietin Response in Diabetic Patients/M.C. Thomas, M.E. Cooper, О Tsalamandris [et al.]//Arch. Intern. Med. 2005. Vol. 165. P. 466-469.
  • Beg M., Katyal P., Singhal К. O, Akhtar N. Evaluation of serum erythropoeitin response to anaemia in macroalbuminurics of diabetic and non-diabetic etiologies//Nepal Med. Coll. J. 2006. Vol.8, №3. P. 1-6.
  • Influence of blood pressure level on urinary albumin excretion rate and erythropoietin production in diabetic patients/L. Bordier, J.P Le Berre, О Garcia [et al.]//Arch. Mai. Coeur Vaiss. 2006. Vol. 99, № 7-8. P. 701-704.
  • Potential roles of erythropoietin in the management of anaemia and other complications diabetes/A. Khoshdel, S. Carney, A. Gillies [et al.]//Diabetes Obes Metab. 2008. Vol. 10, №1. P. 1-9.
  • Are low erythropoietin and 1,25-dihydroxyvitamin D levels indicative of tubulo-interstitial dysfunction in diabetes without persistent microalbuminuria?/D. K. Singh, P. Winocour, B. Summerhayes [et al.]//Diabetes Res. Clin. Pract. 2009. Vol. 85, № 9. P. 258-264.
  • The high prevalence of unrecognized anaemia in patients with diabetes and chronic kidney disease: a population-based study/J. P. New, T. Aung, PG. Baker [et al.]//Diabet Med. 2008. Vol. 25, № 5. P. 564-569.
  • Over-representation of diabetic patients with renal anaemia in the primary care setting/S. Mostafaa, S. Tagbotoa, M. Robinsonb [et al.]//Family Practice. 2009. Vol. 26. P. 180-182.
  • The prevalence of anaemia in diabetes with stage 3 chronic kidney disease: a retrospective analysis/U.Y. Raja, J. Chan, E. Radford [et al.]//The British Journal of Diabetes & Vascular Disease. 2011. Vol. 11, № 9. P. 259-261.
  • Artunc F., Risler T. Serum erythropoietin concentrations and responses to anaemia in patients with or without chronic kidney disease//Nephrol. Dial. Transplant. 2007. Vol. 22, № 10. P. 2900-2908.
  • Fantacci M., Bianciardi P., Caretti A. Carbamylated erythropoietin ameliorates the metabolic stress induced in vivo by severe chronic hypoxia//Proc. Natl. Acad. Sci. 2006. Vol. 103, №4-6. P. 17531-17536.
  • Marsden J.T. Erythropoietin -measurement and clinical applications//Ann. Clin. Biochem. 2006. Vol. 43, № 2. P. 97-104.
  • Singh D.K., Winocour P., Farrington K. Erythropoietic stress and anemia in diabetes mellitus//Nat. Rev. Endocrinol. 2009. Vol. 5, №4. P. 204-210.
  • Singh D.K., Winocour P., Farrington K. Mechanisms of disease: the hypoxic tubular hypothesis of diabetic nephropathy//Nat. Clin. Pract. Nephrol. 2008. Vol. 4, № 4. P. 216-226.
  • Adaptation to hypoxia in the diabetic rat kidney/C. Rosenberger, M. Khamaisi, Z. Abassi [et al.]//Kidney Int. 2008. Vol. 73, № 1. P. 34-42.
  • Lim S.K., Park S.H. High glucose stimulates the expression of erythropoietin in rat glomerular epithelial cells//Lab. Anim. Res. 2011. Vol. 27, № 9. P. 245-250.
  • Raupp D., Vogt C, Dreyhaupt J., Hasslacher С Influence of metabolic control on hemoglobin level in type 1 diabetic patients with nephropathy//Med. Klin. (Munich). 2008. Vol. 103, №4. P. 185-189.
  • Бондарь И. А., Климентов В. В., Надеев А. П. Мочевая экскреция провоспалительных цитокинов и трансформирующего фактора роста-р на ранних стадиях диабетической не-фропатии//Тер. архив. 2008. № 1. С. 52-56.
  • Erythropoietin prevents reactive oxygen species generation and renal tubular cell apoptosis at high glucose level/J. Dang, R. Jia, Y. Tu [et al.]//Biomed. Pharmacother. 2010. Vol. 64, № 12. P. 681-685.
  • Erythropoietin prevents diabetes-induced podocyte damage/M. Schiffer, J. K. Park, I. Tossidou [et al.]//Kidney Blood Press Res. 2008. Vol. 31, № 6. P. 411-415.
  • Effect of erythropoietin on urinary liver-type fatty-acid-binding protein in patients with chronic renal failure and anemia/T. Nakamura, T. Sugaya, Y. Kawagoe [et al.]//Amer. J. Nephrol. 2006. Vol. 26. P. 276-280.
  • The continuous erythropoietin receptor activator affects different pathways of diabetic renal injury/J. Menne, J.K. Park, N. Shushakova [et al.]//J. Amer. Soc. Nephrol. 2007. Vol. 18. P. 2046-2053.
  • Garcia-Ramirez M., Hernandez C, Simo R. Expression of Erythropoietin and Its Receptor in the Human Retina: a comparative study of diabetic and nondiabetic subjects//Diabetes Care. 2008. Vol. 31, №.6. P. 1189-1194.
  • Erythropoietin Is Highly Elevated in Vitreous Fluid of Patients With Proliferative Diabetic Retinopathy/Y Katsura, T. Okano, K. Matsuno [et al.]//Diabetes Care. 2005. Vol. 28, № 9. P. 2252-2254.
  • Lim J.W., Han J.R. Aqueous humour levels of vascular endothelial growth factor and erythropoietin in patients with diabetic macular oedema before and after intravitreal erythropoietin injection//Clin. Experiment. Ophthalmol. 2011. Vol. 39, № 8. P. 537-544.
  • Erythropoietin as a Retinal Angiogenic Factor in Proliferative Diabetic Retinopathy/D. Watanabe, K. Suzuma, S. Matsui [et al.]//N. Engl. J. Med. 2005. 2005. Vol. 353. P. 782-792.
  • Erythropoietin (Epo) and its Receptors in Rat Models of Type I and II Diabetic Retinopathy/N. Mathalone, F. Altomare, M. Sit [et al.]//Invest. Ophthalmol. Vis. Sci. 2006. Vol. 47, № 5. P. 3865-3866.
  • Association between erythropoietin gene polymorphisms and diabetic retinopathy/S. Abhary, K. P. Burdon, R. J. Casson [et al.]//Arch. Ophthalmol. 2010. Vol. 128, №1. P. 102-106.
  • Expression of erythropoietin receptor in human epiretinal membrane of proliferative diabetic retinopathy/S. Kase, W. Saito, K. Ohgami [et al.]//Br.J. Ophthalmol. 2007. Vol. 91. P. 1376-1378.
  • Wang Z. Y, Zhao К. K., Zhao P. Q. Erythropoietin therapy for early diabetic retinopathy through its protective effects on retinal pericytes//Med. Hypotheses. 2011. Vol. 76, № 2. P. 266-268.
  • EPO attenuates inflammatory cytokines by Muller cells in diabetic retinopathy/X. Lei, J. Zhang, J. Shen [et al.]//Front. Biosci. (Elite Ed). 2011. Vol. 3, №1. P. 201-211.
  • A hypothesis: can erythropoietin administration affect the severity of retinopathy in diabetic patients with renal failure?/C.J. Diskin, T.J. Stokes, L. M. Dansby [et al.]//Amer.J. Med. Sci. 2007. Vol. 334, № 10. P. 260-264.
  • Anemia Wth Erythropoietin Deficiency Occurs Early in Diabetic Nephropathy/D.R. Bosman, A.S. Wnkler, J.T. Marsden [et al.]//Diabetes Care. 2001. Vol. 24, № 3. P. 495-499.
  • Blunted erythropoietin response to anemia in patients with Type I diabetes/P Cotroneo, B. Maria Ricerca, L. Todaro [et al.]//Diabetes Metab. Res. Rev. 2000. Vol. 16, № 5-6. P. 172-176.
  • Erythropoietin-dependent anaemia: a possible complication of diabetic neuropathy/S. Hadjadj, F. Torremocha, A. Fanelli [et al.]//Diabetes Metab. 2001. Vol. 27, № 6. P. 383-385.
  • Influence of blood pressure profile on erythropoietin levels in diabetics/H. Mayaudon, O. Dupuy, M. Dolz [et al.]//Arch. Mai. Coeur. Vaiss. 2002. Vol. 95, № 7-8. P. 743-746.
  • Zukowska-Szczechowska E., Tomaszewski M., Sedkowska A., Grzeszczak W. Erythropoietin administration in diabetic patients//Przegl. Lek. 2003. Vol. 60, № 8. P. 532-535.
  • Wnkler A.S., Landau S., Watkins PJ. Erythropoietin treatment of postural hypotension in anemic type I diabetic patients with autonomic neuropathy: a case study of four patients//Diabetes Care. 2001. Vol. 24, №6. P. 1121-1123.
  • Erythropoietin both protects from and reverses experimental diabetic neuropathy/R. Bianchi, B. Buyukakilli, M. Brines [etal.]//PNAS. 2004. Vol. 101, №1. P. 823-828.
  • Erythropoietin during hypoglycaemia in type 1 diabetes: relation to basal rennin-angiotensin system activity and cognitive function/PL. Kristensen, T. Hoi-Hansen, N.V Olsen [et al.]//Diabetes Research and Clinical Practice. 2009. Vol. 85, № 7. P. 75-84.
  • Choi D., Retnakaran R., Woo M. The extra-hematopoietic role of erythropoietin in diabetes mellitus//Curr. Diabetes Rev. 2011. Vol.7, №7. P. 284-290.
  • Erythropoietin protects against diabetes through direct effects on pancreatic beta cells/D. Choi, S.A. Schroer, S.Y Lu [etal.]//J.Exp. Med. 2010. Vol. 207. P. 2831-2842.
  • Improved Glycemic Control in Diabetic Patients Treated with Recombinant Human Erythropoietin/O. Katz, N. Golishevski, H.S. Oster [et al.]//Blood. 2006. Vol. 108, № 11. P. 4228-4229.
  • Erythropoietin treatment leads to reduced blood glucose levels and body mass: insights from murine models/O. Katz, M. Stuible, N. Golishevski [et al.]//J. Endocrinol. 2010. Vol. 205, № 4. P. 87-95.
Еще
Статья научная
QR-код для установки приложения SciUp Наведите камеру и скачайте бесплатное приложение SciUp